-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Breaking News Briefs
The FoundationOne CDx (F1CDx) test received full U.S. Food and Drug Administration (FDA) approval. F1CDx is the first breakthrough-designated, next-generation sequencing–based in vitro diagnostic (IVD) test to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. Simultaneous to FDA approval, the Centers for Medicare & Medicaid Services (CMS) proposed…
-
ALK Testing in Europe
By Enriqueta Felip, MD, PhD Posted: February 2018 ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with stage IV adenocarcinomas of the lung for ALK aberrations is supported by international guidelines.1,2 In Europe, there are also a number of published national guidelines supporting ALK testing in…
-
Immunotherapy Adverse-Event Treatment Resource Guide
The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline to support nurses and allied health providers in managing side effects from immunotherapy, which are different from the side effects from chemotherapy and other traditional lung cancer treatments. This can assist…
-
Lung Cancer Immunotherapy Meeting to Discuss New Topics, Emerging Themes
Posted: February 2018 During the past few years, improvements in the knowledge of immune system biology have dramatically changed the therapeutic paradigm for NSCLC. Pembrolizumab has been recently approved by regulatory agencies as an upfront agent for patients with advanced NSCLC with 50% or greater programmed cell death ligand 1 (PD-L1) expression, and recent data…
-
Bruce Ratner
New IASLC Foundation Board Member Posted: February 2018 Mr. Ratner is the Executive Chairman of Forest City Ratner Cos., a New York-based real estate development company, which he started in 1985. As the founder of one of the largest urban real estate developers in the country, Mr. Ratner has developed 52 ground-up projects in the…
-
Funding Fellowships to Find a Cure: ‘It’s About the People’
By AnnMarie Estrada, IASLC Foundation Director Posted: February 2018 When you think of the IASLC, you think about professional development, networking, and renowned international lung cancer conferences. When you consider the IASLC Foundation, what comes to mind? At first, you may think of fellowships and grants. When we look a little closer, we begin to…
-
Management of Immunotherapy Toxicity in NSCLC
By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was focused and streamlined. Chemotherapy could be toxic and life threatening, but we had specific warnings and guidelines to give to patients. We now have chemotherapy, targeted therapies, and immunotherapy…
-
Inaugural Africa Conference: Finding Parallels Among Disparate Realities
New collaborative meeting to provide educational, scientific updates to diverse audience from Africa and the Middle East. By Joy Curzio, ILCN Managing Editor Posted: February 2018 As a global association, the IASLC understands the numerous variables, experiences, and perspectives that dictate a country’s or region’s ability to be a principal actor in scientific events. For…
-
An American Perspective on the European Lung Cancer Screening Implementation Plans
International sharing of best practices may improve quantitative imaging quality for low-dose CT for small nodules. By James L. Mulshine, MD Posted: February 2018 It is heartening to learn of the decision by thought leaders to begin the process of initiating European implementation of lung cancer screening.1 With this effort, the opportunity exists to off…
-
Improved Turnaround Times for NGS Wait on Improved Technology
Availability of next-generation sequencing continues to improve, but current technology cannot speed turnaround time of results. Posted: February 2018 The standard of care for all patients diagnosed with advanced nonsquamous NSCLC is to undergo genetic testing at diagnosis. “We now know that close to half of all patients with nonsquamous NSCLC will have an oncogenic…